TY - JOUR AU - Burghaus, L. AU - Eggers, C. AU - Timmermann, L. AU - Fink, G.R. TI - Hallucinations in neurodegenerative diseases JO - CNS neuroscience & therapeutics VL - 18 SN - 1755-5949 CY - Oxford PB - Wiley-Blackwell M1 - PreJuSER-21473 SP - 149 - 159 PY - 2012 N1 - Record converted from VDB: 12.11.2012 AB - Patients with neurodegenerative disease frequently experience hallucinations and illusionary perceptions. As early symptoms, hallucinations may even have diagnostic relevance (i.e., for the diagnosis of Lewy Body Dementia). In the later course of the disease, hallucinations may appear as characteristic symptoms and often constitute a particular challenge for therapeutic endeavors. Here, the distinction of disease-inherent hallucinations from medication-associated perceptual disturbances is particularly relevant. Synucleinopathies and tauopathies have different risk profiles for hallucinations. In synucleinopathies hallucinations are much more frequent and phenomenology is characterized by visual, short-lived hallucinations, with insight preserved for a long time. A “double hit” theory proposes that dysfunctionality of both associative visual areas and changes of limbic areas or the ventral striatum are required. In contrast, in tauopathies the hallucinations are more rare and mostly embedded in confusional states with agitation and with poorly defined or rapidly changing paranoia. The occurrence of hallucinations has even been proposed as an exclusion criterion for tauopathies with Parkinsonian features such as progressive supranuclear palsy. To date, treatment remains largely empirical, except the use of clozapine and cholinesterase inhibitors in synucleinopathies, which is evidence-based. The risk of increased neuroleptic sensitivity further restricts the treatment options in patients with Lewy Body Dementia. Coping Strategies and improvement of visual acuity and sleep quality may be useful therapeutic complements. KW - Adaptation, Psychological KW - Animals KW - Hallucinations: epidemiology KW - Hallucinations: psychology KW - Hallucinations: therapy KW - Humans KW - Neurodegenerative Diseases: epidemiology KW - Neurodegenerative Diseases: psychology KW - Neurodegenerative Diseases: therapy KW - Parkinson Disease: epidemiology KW - Parkinson Disease: psychology KW - Parkinson Disease: therapy KW - Sleep Disorders: epidemiology KW - Sleep Disorders: psychology KW - Sleep Disorders: therapy KW - J (WoSType) LB - PUB:(DE-HGF)16 C6 - pmid:21592320 UR - <Go to ISI:>//WOS:000300001700008 DO - DOI:10.1111/j.1755-5949.2011.00247.x UR - https://juser.fz-juelich.de/record/21473 ER -